- Global Pharma News & Resources

Pall Corporation and Celltheon Form Strategic Partnership for Biotherapeutics Development and Manufacturing with CELLTHEON SMART™ Expression Platform

Pall Corporation and Celltheon Form Strategic Partnership for Biotherapeutics Development and Manufacturing with CELLTHEON SMART™ Expression Platform

PR Newswire

PORT WASHINGTON, N.Y., Sept. 4, 2018

PORT WASHINGTON, N.Y., Sept. 4, 2018 /PRNewswire/ -- Pall Corporation, a global leader in filtration, separation and purification, has formed a strategic partnership with Celltheon Corporation, an experienced cell line and expression technology platform development company. This partnership aligns Pall Biotech equipment and consumables with the Celltheon SMARTTM Expression Platform to deliver integrated manufacturing solutions for customers developing biotherapeutics. It is part of Pall's strategic approach to forming key partnerships that help enable better, safer and faster biologic production.

"The Pall Biotech portfolio was built to support drug manufacturers at all stages of biotherapeutic molecule development and processes to improve biologic production, and ultimately, global health," said Mario Philips, VP & General Manager of Pall Biotech. "Pall's strategic partnerships, such as this one with Celltheon, aim to overcome manufacturing challenges with efficient, integrated and cost-effective total solutions."

"The CELLTHEON SMARTTM Expression Platform is an off-the-shelf, fully validated mammalian cell platform used to develop biologics and it is well complemented by the Pall Biotech line of equipment and services," said Amita Goel, CEO, founder and chairman of Celltheon. "With the complementary Celltheon and Pall technologies, we can provide an integrated end-to-end solution for research and bioproduction that is cost effective and time efficient. This partnership with Pall Corporation is in line with Celltheon's mission to expedite drug development and provide solutions for unmet needs in bioprocessing."

Through the agreement, Celltheon customers will have immediate access to various Pall Biotech upstream and downstream processing technologies, including bioreactors, mixing and storage, downstream technologies, and consumables.

About Pall Corporation
Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.
For more information visit

Or follow us on social media: Google+ - YouTube -   LinkedIn - Twitter - Facebook

About Celltheon Corporation
Celltheon Corporation is focused on cell line and process development for biologics manufacturing. The team offers off-the-shelf, yet customizable solutions for the expression of a wide variety of recombinant proteins via the proprietary Celltheon SMARTTM Expression Platform of technologies and services. Celltheon has developed and integrated consistent and high productivity technologies at every step in the upstream bioproduction process. The Celltheon SMARTTM Expression Platform has been validated on a number of pre-clinical and clinical stage molecules. Learn more about reducing time and cost to market with the right partner at:

For more information on working with Celltheon, please contact

Pall Corporate Media Contact
Pall Corporation
Mariann Kourafas
Director of Communications

Pall Media Contact
White Matter Communications
Beth Willers

View original content:

SOURCE Pall Corporation

Editor Details

Last Updated: 04-Sep-2018